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Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biologic activities in immune regulation, hematopoiesis,
inﬂammation, and oncogenesis. Recent accumulating evidence indicates a pathologic role for IL-6 in promoting proliferation
of both smooth muscle and endothelial cells in the pulmonary arterioles, resulting in development of pulmonary arterial
hypertension (PAH). Here, we describe a patient with mixed connective tissue disease and severe, refractory PAH. Her functional
activity and hemodynamic parameters dramatically responded to tocilizumab, a humanized monoclonal antibody to human IL-6
receptor, which was aimed at treating multicentric Castleman’s disease. It appears that IL-6 blockade may hold promise as an
adjunct drug in treatment of PAH in idiopathic form as well as in association with connective tissue disease.
1.Introduction
Pulmonary arterial hypertension (PAH) is a cause of signif-
icant morbidity and mortality in patients with connective
tissue disease (CTD), especially in those with systemic
sclerosis (SSc) or mixed connective tissue disease (MCTD)
[1]. In fact, a survival study over the past 30 years in
consecutivepatientsevaluatedattheUniversityofPittsburgh
has demonstrated that PAH became the primary cause
of SSc-related deaths today [2]. PAH is characterized by
increased pulmonary vascular resistance due to remodeling
of the pulmonary arterioles. Left untreated, PAH leads irre-
mediably to right ventricular hypertrophy, pressure overload
and dilation, and impaired cardiac output, resulting in death
[3]. Until recently, there was no eﬀective therapy for PAH, a
diseasewithamediansurvivalestimatedtobeapproximately
one year following the diagnosis in patients with SSc [4].
However, in the past two decades, novel therapies have
been developed, focusing on vasoactive substances derived
from the pulmonary vascular endothelium [5]. These sub-
stances, such as endothelin-1, nitric oxide, and prostacyclin
regulate smooth muscle cell tone and proliferation and
were shown to be central to the pathogenesis of PAH
[6]. Therefore, current therapeutic agents target these 3
essential biological pathways: the endothelin-1/endothelin
receptor, nitric oxide/cGMP, and prostacyclin/cAMP path-
ways. Improvement of symptoms, functional activity, and
quality of life and even prolongation of survival have been
partially achieved with currently available therapies, but
mostly in patients with idiopathic PAH [5]. Indeed, it has
become clearer in the past few years that SSc patients with
PAHhaveastrikinglydivergentresponsetocurrenttherapies
and overall worse outcome compared with patients with
idiopathic PAH in spite of seemingly milder hemodynamic
impairment [7, 8]. In a recent multicentre longitudinal study
to evaluate 3-year survival in SSc patients, 20 of 47 patients
with PAH died during follow-up, giving a 3-year survival
of only 56%, despite the fact that they were treated with
modern PAH drugs [9]. Even in SSc patients with mildly
symptomatic PAH in New York Heart Association (NYHA)
functional class II, approximately two-thirds deteriorated
to functional class III or IV, and some died during a
5-year period, although they were treated with one or
more PAH drugs [10]. While there have been signiﬁcant2 International Journal of Rheumatology
advances in the treatment of PAH, survival of patients with
PAH associated with CTD on modern PAH drugs remains
unacceptably low. Therefore, novel therapeutic strategies
targeting pathways beyond pulmonary vascular endothelium
arerequiredtofurtherimprovesurvivalofCTDpatientswith
PAH.
We have recently experienced a rare case of PAH-CTD
complicated by multicentric Castleman’s disease (MCD)
during the course of the disease. MCD was successfully
treated with tocilizumab, a humanized antihuman inter-
leukin6 (IL-6) receptor monoclonal antibody, which dra-
matically improved functional activity and hemodynamic
parameters of PAH as well.
2.CaseReport
A 45-year-old woman ﬁrst noticed polyarthralgia and puﬀy
ﬁngers in 1997 and developed slowly progressive dyspnea
on exertion, which made her hospitalization in a regional
hospital in 2001. Pulmonary hypertension was detected
by transthoracic echocardiography, which showed mild
right ventricular hypertrophy in conjunction with abnor-
mal contour of the interventricular septum and increased
systolic pulmonary arterial pressure (PAP) (100mmHg)
estimated by Doppler echocardiography. Interstitial lung
disease (ILD) and pericardial eﬀusion were also detected.
Taken together with increased levels of C-reactive protein
(CRP),positive antinuclear, and anti-U1RNP antibodies, she
was diagnosed as having mixed connective tissue disease
(MCTD) complicating pulmonary hypertension. She was
treated with corticosteroid pulse therapy followed by high-
dose prednisolone (1mg/kg), resulting in improvement of
exertional dyspnea and reduction in estimated systolic PAP
to60mmHg.InNovember2005,shevisitedapulmonologist
of the referring centre because of worsening dyspnea. She
underwent a systematic cardiac evaluation, including right
heart catheterization and ventilation-perfusion scan, and a
diagnosis of PAH in NYHA functional class III was made
based on mean PAP 58 mmHg, pulmonary capillary wedge
pressure (PCWP) 10mmHg, cardiac output 3.4L/min, and
pulmonary vascular resistance (PVR) 14.4 Wood units. The
6-minute walk distance (6MWD) was only 300 meters.
Bosentan 250mg was initiated with oxygen supplementation
inJanuary2006,withsubtleimprovementofexertionaldysp-
nea.Aftersummerof2007,hersymptomgraduallyworsened
again. In addition, she experienced low-grade fever, loss
of appetite, and body weight loss (−5kg/6 months) with
cervical lymphoadenopathy and hepatosplenomegaly, which
had worsened despite the use of low-dose prednisolone. She
wasreferredtoourhospitalforadditionalevaluationintothe
etiology of PAH in April 2008.
She had marked limitation of physical activity (NYHA
functional class III), and 6MWD was only 310 meters.
Physical examination demonstrated jugular venous dilata-
tion, lower extremity edema, and lymphoadenopathy on
cervical, axillary, and inguinal lesions. Nailfold capillary
changes were found, but sclerodactyly, muscle weakness,
arthritis, and butterﬂy rash were absent. Laboratory data
showed marked anemia (hemoglobin 8.1g/dL), hypoalbu-
minemia (2.9g/dL), polyclonal hypergammaglobulinemia
with IgG 6451mg/dL, CRP 9.1mg/dL, brain natriuretic
peptide (BNP) 181pg/mL, a positive antinuclear antibody at
a titer of 1:1,280 with pure speckled pattern, and a positive
anti-U1 RNP antibody (86 Index; normal range <15). The
protrusion of the main pulmonary artery, increased width
of the descending branch of the right pulmonary artery,
and an increase in the cardiothoracic ratio were noted on
chestX-ray(Figure 1).Electrocardiogramshowedsignsofan
increased right heart load. Hemodynamics assessed by right
heart catheterization included man PAP 43mmHg, PCWP
11mmHg, right atrial pressure (RAP) 12mmHg, cardiac
output 5.5L/min, and PVR 5.8 Wood units, indicating that
2-year treatment with bosentan partially improved these
parameters. High-resolution computed tomography showed
ground-glass opacities with minimal honeycomb cysts on
bilateral lower lung ﬁeld, dilatation of the right atrium,
right ventricle, and central pulmonary arteries, and multiple
mediastinal lymphadenopathy. Histological evaluation of
the biopsied axillary lymph node demonstrated an intense
plasmacytosis in the interfollicular areas with a prominent
increase in capillaries and postcapillary venules, some of
which were hyalinized. These ﬁndings were compatible with
MCD in mixed histological features of plasma cell and
hyaline vascular types [11]. Serology for human immun-
odeﬁciency virus (HIV) or human herpesvirus type 8
(HHV-8) was negative. Cytomegalovirus antigenemia was
undetectable. Gene sequence for HHV-8 or Epstein-Barr
virus was not found in the lymph node. A markedly elevated
level of serum IL-6 (41.8pg/mL; normal range <4) was
consistent with the diagnosis of MCD [12].Thus,we decided
to ﬁrst treat concomitant MCD with tocilizumab at a dose of
8mg/kgevery2weeks.
Serial functional, hemodynamic, and laboratory param-
eters before and after the tocilizumab treatment are sum-
marized in Table 1. After 4 infusions of tocilizumab, low-
g r a d ef e v e ra n dl o s so fa p p e t i t ew e r ec o m p l e t e l yg o n e ,a n d
fatigue was prominently improved with normalization of
hemoglobin level. A prominent increase in circulating IL-6
concentration after introduction of tocilizumab indicated
eﬃcient IL-6 receptor blockade. Lymphadenopathy and
hepatosplenomegalyweregraduallyresolvedandwereﬁnally
undetectable at 3 months after introduction of tocilizumab.
Functional activity was gradually improved to NYHA func-
tional class II and 434 meters at 6MWD. BNP was decreased
to48pg/mL.Rightheartcatheterizationat3monthsrevealed
that mean PAP was reduced to 31mmHg and RAP was
5mmHg. There was no improvement in cardiac output or
PVR,butcardiacoutputwascalculatedwiththeFickmethod
by an equation containing a hemoglobin level, which rose up
markedly after the tocilizumab treatment. In fact, systemic
venous oxygen saturation had dramatically improved from
52.1% to 69.4%. Her dyspnea has continued to improve
and was ﬁnally undetectable (NYHA functional class I) at
6 months when oxygen supplementation was discontinued.
The increased right heart load ﬁndings on chest X-ray
were remarkably improved (Figure 1). After 12 months of
treatment with tocilizumab, she was in NYHA functionalInternational Journal of Rheumatology 3
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Figure 1: Chest X-ray before tocilizumab and after 6-month treatment with tocilizumab.
c l a s sIa n dw a sa b l et ow a l k6 6 3m e t e r sa t6 M W Dw i t h o u t
reduction of arterial oxygen saturation. The mean PAP was
further decreased to 27mmHg. The patient has been in
NYHA functional class I and in remission of MCD on
biweekly tocilizumab, as of May 2010. No side eﬀect of the
tocilizumab treatment was apparent.
3. IL-6 Overproduction and PAH
MCD is a rare lymphoproliferative disorder characterized by
systemic lymphadenopathy and constitutional inﬂammatory
symptoms [11]. Patients with MCD frequently have systemic
manifestations, such as low-grade fever, fatigue, loss of
appetite, and weight loss. Abnormal laboratory ﬁndings
include anemia, hypoalbuminemia, hypergammaglobuline-
mia, and increased acute-phase proteins such as CRP.
The etiology of the disease appears to be heterogeneous,
but dysregulated overproduction of IL-6 is believed to be
responsible for the clinical abnormalities [12]. In fact, IL-6
transgenic mice represented the disease phenotype resem-
bling MCD, which was successfully treated with an anti-IL-6
receptor antibody [13]. In a multicenter prospective study to
evaluate the eﬃcacy of tocilizumab in patients with MCD,
objective improvement was consistently observed in clinical
symptoms, lymphadenopathy and other physical ﬁndings,
and laboratory parameters [14]. In addition, HHV-8 is
reported to be an etiologic agent of MCD, especially in
patients infected with HIV [15], since HHV-8 encodes a
human IL-6 homolog, which shares functional properties
with human IL-6 [16].
PAHisararecomplicationofMCD[11],andonly4cases
diagnosed with both of these conditions have been reported
previously [17–19]. These case reports raise several hypothe-
ses linking PAH and MCD. One hypothesis includes an asso-
ciationofPAHwithHHV-8infectionratherthanMCDitself.
HHV-8 encodes genes homologous to human genes involved
incellproliferation,antiapoptosis,andangiogenesis[20,21],
and HHV-8 gene sequences have been found in plexiform
lesionsderivedfromsomepatientswithidiopathicPAH[22],
suggesting the possibility that HHV-8 could be involved in
the misguided angiogenesis characteristic of PAH. However,
HHV-8 infection was not detected in our case as well as in
another 2 reported cases complicating MCD and PAH [17,
19]. One of the reported case infected with HIV and HHV-8
showed an unusual complete reversibility of both MCD and
severe PAH, with an immunosuppressive treatment with
cyclophosphamide, together with highly active antiretroviral
therapy and epoprostenol [18]. In addition, tocilizumab
induced partial remission of both MCD and PAH in our case
as well as in the other HHV-8-uninfected case [19]. These
case reports raise another hypothesis that IL-6 is a common
pathogenic factor in both MCD and PAH.
Patients with idiopathic PAH are consistently found to
have an increased level of IL-6 in circulation [23, 24]a n d
in lung tissue [25]. In patients with lupus, MCTD, or SSc, a
higher serum IL-6 level was reported in patients with PAH
than in those without PAH [26–28]. In addition, elevated
serum IL-6 was reported in patients with POEMS (polyneu-
ropathy, organomegaly, endocrinopathy, monoclonal gam-
mopathy, and skin changes) syndrome, a rare variant of
plasma cell dyscrasia, which sometimes complicates PAH
[29]. Several animal models of PAH, including chronic
hypoxia [30] and monocrotaline treatment [31], are also
associatedwithincreasedproductionofIL-6.Moreover,daily
subcutaneous injection of recombinant IL-6 in rats induced
the medial thickness of small pulmonary arteries, leading
to PAH [32]. These ﬁndings together suggest that PAH
development is associated with IL-6 overproduction.
4 .R o l e so fI L - 6inP a t h og e n e s iso fP A H
IL-6 is a pleiotropic cytokine with a wide range of biologic
activities in immune regulation, hematopoiesis, inﬂamma-
tion, and oncogenesis [33]. Accumulating evidence indicates4 International Journal of Rheumatology
Table 1: Serial functional, hemodynamic, and laboratory parameters before and after the tocilizumab treatment.
Pretreatment 3 months 6 months 9 months 12 months
NYHA functional class III II I I I
6MWD (m) 310 434 ND ND 663
Mean PAP (mmHg) 43 31 ND ND 27
PCWP (mmHg) 11 4 ND ND 4
RAP (mmHg) 12 2 ND ND 3
Systemic venous oxygen saturation (%) 52.1 69.4 ND ND 75.3
Cardiac output (L/min) 5.5 4.5 ND ND 4.4
PVR (wood unit) 5.8 5.6 ND ND 5.3
Doppler systolic PAP (mmHg) 100 90 72 51 54
BNP (pg/mL) 181 48 44 46 37
CRP (mg/dL) 9.01 0.54 0.25 0.12 0.04
IgG (mg/dL) 6,451 3,266 2,679 2,433 2,238
Hemoglobin (g/dL) 8.0 12.9 13.9 13.0 12.8
IL-6 (pg/mL) 41.8 1,100 801 806 756
ND, 6MWD and hemodynamic assessment by right heart catheterization were not done at 6 and 9 months.
pathological roles for IL-6 in various disease conditions,
such as inﬂammatory, autoimmune, and neoplastic diseases.
Pathologic features in patients with PAH are characterized
bymuscularizationofdistalpulmonaryarterioles,concentric
intimal thickening, and obstruction of the vascular lumen
by proliferating endothelial cells to form plexiform lesions
[34]. It has been proposed that dysregulated cellular growth
and apoptosis are responsible for a typical proliferative
cellular phenotype, resulting in pulmonary vascular remod-
eling in PAH. On the other hand, perivascular inﬁltration
of inﬂammatory cells, consisting of T cells, B cells, and
macrophages, are often present within and around the
aﬀected pulmonary arteries of patients with PAH, suggesting
thatcytokinesandgrowthfactorssecretedfromtheseinﬂam-
matory cells may be involved in uncontrolled proliferation
of pulmonary artery smooth muscle and endothelial cells
[35].
In this regard, a lung-speciﬁc overexpression of IL-6 in
mice resulted in increased PVR and pathological lesions
similar to that seen in patients with PAH, including dis-
tal arteriolar muscularization, plexogenic arteriopathy, and
periarteriolar inﬁltration of T cells [36]. These ﬁndings
indicate that IL-6 directly or indirectly promotes prolifer-
ation of both smooth muscle and endothelial cells, which
are potentially mediated through a number of proliferative,
prosurvival, and anti-apoptotic processes (Figure 2). In this
regard, IL-6 triggers vascular smooth muscle cell prolifera-
tion through upregulated expression of vascular endothelial
growth factor (VEGF) and its receptor VEGFR2 [36, 37],
which was observed in the plexiform lesions of patients with
PAH [38].
It has been known that transforming growth factor
(TGF)-β/bone morphogenetic protein (BMP) signaling con-
trols growth of vascular smooth muscle and endothelial cells
by inhibiting excessive proliferation. Genetic mutations in
the gene encoding the type II receptor of BMP (BMPR2)
comprise a genetic hallmark of heritable PAH [39], and
downregulated protein expression of BMPR2 has also been
described in nonheritable PAH [40]. A recent study by Brock
et al. demonstrated that IL-6 repressed protein expression of
BMPR2 through overexpression of microRNA cluster 17/92
[41]. MicroRNAs regulate posttranslational mechanisms by
binding to their target mRNAs and by altering mRNA
stability or aﬀect protein translation [42]. Interestingly,
protein expression of TGFβR2, another receptor from the
identical protein family, was also modulated by the same
microRNAcluster[43].ThismayexplainthelackofTGFβR2
expression in plexiform lesions of patients with PAH [44].
The promoter region of the microRNA 17/92 gene C13 or
f25 has a highly conserved binding site for STAT3, a major
IL-6 signal transduction pathway [33]. In fact, persistent
activation of STAT3 resulted in repressed protein expression
of BMPR2 [41].
Angiopoietin-1 (Ang-1)-Tie2 pathway is essential for
both embryonic and postnatal angiogenesis and involves
in a protective action on endothelial cells by suppressing
inﬂammation and apoptosis [45] .T h er o l eo ft h i ss y s t e mi n
the pathogenesis of PAH has been poorly understood, but a
recentstudyusingTie2-deﬁcientmicefoundthatendothelial
survivalsignaling via the Ang-1-Tie2 pathwayis protective in
PAH [46]. Exposure of IL-6 decreased expression of Ang-1
in lung vascular smooth muscle cells, leading to reduction
of Tie2 activity in endothelial cells and resultant excessive
apoptosis.
On the other hand, a constitutive activation of STAT3
was described in vascular smooth muscle cells as well
as in endothelial cells from the lung tissue of patients
with PAH [47]. Upon stimulation with IL-6, endothelial
cells produce CX3CL1/fractalkine, a potent chemokine that
recruits monocytes and lymphocytes into the lung [48].
These mononuclear inﬁltrates are major source of IL-6,
but vascular smooth muscle cells and endothelial cells also
produce IL-6 upon stimulation with IL-6 [36, 49]. Taken
together, IL-6 promotes the development and progressionInternational Journal of Rheumatology 5
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Figure 2: Hypothetical mechanism leading to pulmonary vascular remodeling via overexpression of IL-6. IL-6 induced proliferation and
antiapoptosis in vascular smooth muscle cells through upregulation of VEGF, and downregulation of BMPR2 and TGFβR2. Upon IL-6
exposure, endothelial cells undergo apoptosis through repressed Tie2 signaling via downregulated Ang-1 expression in smooth muscle cells.
Production of CX3CL1 results in recruitment of inﬂammatory cells, such as lymphocytes and monocytes, which produce enormous amount
of IL-6, while vascular smooth muscle and endothelial cells also produce IL-6 upon stimulation with IL-6.
of pulmonary vascular remodeling, leading to PAH, via a
variety of mechanisms.
5 .T h e“ Sec o n d - H it ”P r oc e s sf o r
DevelopingPAH
However, PAH observed in mice undergoing IL-6 overex-
pression was subtle, but was hemodynamically and his-
tologically remarkable upon hypoxia exposure [36, 50].
In contrast, IL-6 knockout mice exposed to hypoxia were
resistant to the development of increased PVR [51]. This is
consistent with the “second-hit” theory for the pathogenesis
of PAH, in which the response to an environmental or
endogenous trigger is enhanced in susceptible individuals
[52]. For example, exposure to serotonergic or inﬂammatory
stressors produced an enhanced pulmonary hypertensive
response in BMPR2 deﬁcient mice [53]. Therefore, it
is likely that overproduction of IL-6 alone has minimal
impact on development of PAH, but the combination with
other factors known to enhance susceptibility to pulmonary
vascular remodeling, such as hypoxia and vasculopathy in
CTD, appears to have synergistic eﬀects resulting in the
development of signiﬁcant PAH.
The contribution of IL-6 to the pathogenesis of PAH
may be diﬀerent among associated conditions. In this regard,
circulating IL-6 level was increased in patients with SSc, and
the increased level was associated with the presence of PAH
[28, 54]. In addition, the IL-6 level in bronchoalveolar lavage
ﬂuid was also increased in patients with SSc irrespective of
the presence or absence of interstitial lung disease [55]. IL-6
is abundantly produced in vitro by aﬀected skin ﬁbroblasts
and alveolar macrophages derived from patients with SSc
[56, 57]. These ﬁndings together indicate that the lung tissue
of SSc patients is always exposed to IL-6. This may explain
why prevalence of PAH is the most frequent in patients with
SSc among CTDs.
6.SummaryandFuturePerspectives
Current therapeutic strategies for PAH focus on the pul-
monary vascular endothelium and its role in regulating
smooth muscle cell tone and proliferation. By using these
modern PAH drugs, treatment of PAH has undergone an
extraordinary evolution even in patients with CTD, but PAH
still remains a chronic intractable disease without a cure.
A better understanding of the underlying pathophysiology
of the pulmonary vasculature is needed for better therapy.
In this regard, the ﬁndings of pathologically aberrant
proliferation of smooth muscle and endothelial cells as
well as increased expression of secreted growth factors,
such as VEGF and platelet-derived growth factor (PDGF),
in PAH have caused a shift in paradigm in treatment
strategies for this disease [58]. The eﬃcacy of imatinib, a
prototypicalPDGFreceptorsignalinginhibitor,wasreported
in patients with severe PAH [59–61], and a phase II
multicenter clinical trial of imatinib in patients with PAH
has been completed in the United States and Europe and
the results are pending. On the other hand, our case report
indicates that IL-6 is another potential therapeutic target for
PAH.
In summary, this report describes our experience with
the use of tocilizumab in a patient with MCTD and
PAH. The rationale for such treatment derives from a
numerous basic studies showing a critical role of IL-6
in the promotion of pulmonary vascular remodeling and
consequent development of PAH. The concept underlying
use of IL-6 blockade in PAH is prevention and reversal of
lung vascular remodeling rather than prolonged vasodila-
tion of pulmonary arteries. We recognize the limitations
of a single case report, but we believe that blockade of
IL-6 signaling may be a promising new therapy for PAH,
especially in the context of CTD. Further studies of IL-6
blockade in PAH patients with and without CTD are
warranted.6 International Journal of Rheumatology
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